Faegre Drinker Biddle & Reath LLP, a Delaware limited liability partnership | This website contains attorney advertising.

Overview

By bringing innovative products to market, pharmaceutical companies help people live longer, higher-quality lives — and our attorneys and other professionals are dedicated to facilitating that progress. Our professionals include former in-house counsel and senior executives for some of the world’s largest pharmaceutical companies, as well as an interdisciplinary team of experienced attorneys and professionals who provide regulatory, transactional, litigation, intellectual property and government affairs services tailored to the pharmaceutical industry. We help clients tackle business and financing pressures, regulatory scrutiny and litigation threats on a national and international scale. We have steered global pharma companies through multibillion-dollar transactions and helped international drug manufacturers accelerate drug development through creative joint ventures. Our IP attorneys work to patent your inventions in countries around the globe; shield your brands through trademark policing and anti-counterfeiting strategies; and negotiate commercial, licensing and other strategic agreements — freeing you to focus on product development and innovation. We serve as outside general counsel for regulatory compliance matters and support on all interactions with the Food and Drug Administration and other regulatory parties, including inspections, investigations and enforcement. And when disputes occur, our trial lawyers are there to handle any issue. Whether enforcing your rights or defending against alleged wrongdoing, including in product liability litigation, our team of skilled trial attorneys is ready to represent you in high-stakes, bet-the-company litigation every day.

Insights & Events

Latest

Updates February 2025

China Issues Final Compliance Guidelines in Regulating the Medical Industry

Compliance Guidelines on Preventing Commercial Bribery Risks for Pharmaceutical Enterprises
7 min read  
Updates January 2025

FDA's Final Rule for Laboratory Developed Tests

Significant Impact on the Future of LDTs and the Labs That Offer Them
4 min read  
Updates January 2025

Assessing the Impact of a Revoked Executive Order on a Medicaid Drug Demonstration Project

5 min read  
Updates January 2025

FDA Issues Detailed Guidance for Biopharma Industry on What Information to Provide to FDA About Use of AI Models

A Seven-Step Process and Detailed Recommendations for Submissions
6 min read  
Media Mentions January 2025

Libby Baney Discusses Future of Remote Prescription Regulation Under New Administration With Modern Healthcare

1 min read  
Updates January 2025

State & Local Employment Law Developments: Q4 2024

New Employee Protections and Employer Obligations in Alabama, California, Colorado, Connecticut, Delaware, District of Columbia, Illinois, Indiana, Kentucky, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New York, Oregon, Pennsylvania and Rhode Island
10 min read  
Press Release December 2024

Faegre Drinker Announces 2025 Partner Class and New Counsel Promotions

3 min read  
Speaking Engagement Recap November 20, 2024

Managed Care, Enforcement and Compliance

Healthcare Enforcement Compliance Conference
1 min read  
Speaking Engagement Recap November 18, 2024

Federal and State Enforcement of Private Equity Investment in Health Care

Healthcare Enforcement Compliance Conference
1 min read  
Press Release September 2024

Three Former Federal Prosecutors Join Faegre Drinker’s White Collar Team

5 min read  
Insights
Updates February 2025

China Issues Final Compliance Guidelines in Regulating the Medical Industry

Compliance Guidelines on Preventing Commercial Bribery Risks for Pharmaceutical Enterprises
7 min read  
Updates January 2025

FDA's Final Rule for Laboratory Developed Tests

Significant Impact on the Future of LDTs and the Labs That Offer Them
4 min read  
Updates January 2025

Assessing the Impact of a Revoked Executive Order on a Medicaid Drug Demonstration Project

5 min read  
Updates January 2025

FDA Issues Detailed Guidance for Biopharma Industry on What Information to Provide to FDA About Use of AI Models

A Seven-Step Process and Detailed Recommendations for Submissions
6 min read  
Media Mentions January 2025

Libby Baney Discusses Future of Remote Prescription Regulation Under New Administration With Modern Healthcare

1 min read  
Updates January 2025

State & Local Employment Law Developments: Q4 2024

New Employee Protections and Employer Obligations in Alabama, California, Colorado, Connecticut, Delaware, District of Columbia, Illinois, Indiana, Kentucky, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New York, Oregon, Pennsylvania and Rhode Island
10 min read  
Updates December 2024

Five Major Drug & Medical Device Developments of 2024

13 min read  
Updates December 2024

The Prospects of Dr. Martin Makary and RFK Jr. at HHS, Potential Pharma Tariffs, and EU Guidance on Ethylene Oxide

Biopharma & Medical Devices Briefing
7 min read  
Updates December 2024

Section 301 Petition Pulled, But Tariffs Still on the Horizon

Facing Fentanyl’s Petition Is Withdrawn
3 min read  
Updates November 2024

Updates on Potential Trade Tariffs for the Fentanyl Epidemic

3 min read